文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

1990-2021年全球细菌抗菌药物耐药负担:系统分析及至2050年的预测

Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050.
PubMed 文献 · Lancet · 2024-09-16
一句话结论2021年细菌抗菌药物耐药相关死亡471万、归因死亡114万;预测2050年归因死亡191万,改善重症感染救治与抗生素可及性至2050年可累计避免9200万死亡。

该研究系统评估1990-2021年204个国家22种病原体、84种病原-药物组合和11种感染综合征的细菌抗菌药物耐药归因与相关死亡及伤残调整生命年,并预测至2050年。2021年细菌抗菌药物耐药相关死亡471万(95%UI 4.23-5.19),归因死亡114万(1.00-1.28);1990-2021年5岁以下儿童耐药死亡下降超过50%,70岁及以上成人上升超过80%。预测2050年归因死亡191万、相关死亡822万;改善重症感染救治与抗生素可及性情景下2025-2050年可累计避免9200万死亡,革兰阴性菌药物研发情景下可避免1110万耐药死亡。

要点

  • 2021年细菌抗菌药物耐药相关死亡471万(95%UI 4.23-5.19),归因死亡114万(1.00-1.28)。
  • 1990-2021年5岁以下儿童耐药死亡下降超过50%,70岁及以上成人上升超过80%;5岁以下儿童在所有超级区域均下降,5岁及以上人群在所有超级区域均上升。
  • 耐甲氧西林金黄色葡萄球菌相关死亡从1990年26.1万(15.0-37.2万)升至2021年55.0万(50.0-60.0万),归因死亡从5.72万(3.41-8.03万)升至13.0万(11.3-14.6万)。
  • 革兰阴性菌对碳青霉烯类耐药相关死亡从1990年61.9万(40.5-83.4万)升至2021年103万(90.9-116万),归因死亡从12.7万(8.21-17.1万)升至21.6万(16.8-26.4万)。
  • 预测2050年归因死亡191万(1.56-2.26)、相关死亡822万(6.85-9.65);改善重症感染救治与抗生素可及性情景下2025-2050年可累计避免9200万死亡(82.8-102.0)。

适用人群与场景

  • 全球204个国家和地区1990-2021年全年龄段及年龄别人群,涵盖22种病原体、84种病原-药物组合和11种感染综合征。
  • 预测至2050年,覆盖全球、超级区域和区域层面。

研究设计与关键结果

  • 研究类型为系统分析,纳入多因死亡数据、医院出院数据、微生物学数据、文献研究、单药耐药谱、药品销售、抗生素使用调查、死亡监测、链接数据、门诊和住院保险索赔数据及既往发表数据,覆盖5.2亿条个人记录或分离株和19513个研究地点-年份。
  • 2021年细菌抗菌药物耐药相关死亡471万(95%UI 4.23-5.19),归因死亡114万(1.00-1.28)。
  • 1990-2021年抗菌药物耐药死亡在5岁以下儿童中下降超过50%,在70岁及以上成人中上升超过80%;5岁以下儿童在所有超级区域均下降,5岁及以上人群在所有超级区域均上升。
  • 耐甲氧西林金黄色葡萄球菌相关死亡从1990年26.1万(15.0-37.2万)增至2021年55.0万(50.0-60.0万),归因死亡从5.72万(3.41-8.03万)增至13.0万(11.3-14.6万)。
  • 革兰阴性菌对碳青霉烯类耐药相关死亡从1990年61.9万(40.5-83.4万)增至2021年103万(90.9-116万),归因死亡从12.7万(8.21-17.1万)增至21.6万(16.8-26.4万)。
  • 2020年和2021年非COVID相关感染性疾病出现显著下降。
  • 预测2050年全球归因死亡191万(1.56-2.26)、相关死亡822万(6.85-9.65);2050年全年龄段抗菌药物耐药死亡率最高的超级区域预测为南亚及拉丁美洲和加勒比。
  • 2050年归因死亡中70岁及以上人群占65.9%(61.2-69.8);2022-2050年归因死亡数增加69.6%(51.5-89.2),伤残调整生命年仅增加9.4%(-6.9至29.0)至4650万(37.7-57.3)。

证据类型、等级与局限

  • 证据类型为系统分析(统计建模),基于多来源数据覆盖5.2亿条个人记录或分离株和19513个研究地点-年份,对无数据地点也进行建模估计。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,鉴于耐药负担随地点和年龄高度可变,干预措施应结合感染预防、疫苗接种、减少农业和人类中不适当抗生素使用以及研究新型抗生素,以减少预测的2050年耐药死亡数。
  • 作者指出,5岁以下儿童耐药死亡下降显示感染预防的重要性,同时70岁以上人群耐药负担呈令人担忧的趋势,且全球人口快速老龄化。
  • 预测显示改善重症感染救治和抗生素可及性可避免大量死亡,作者据此强调综合干预的必要性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Antimicrobial resistance (AMR) poses an important global health challenge in the 21st century. A previous study has quantified the global and regional burden of AMR for 2019, followed with additional publications that provided more detailed estimates for several WHO regions by country. To date, there have been no studies that produce comprehensive estimates of AMR burden across locations that encompass historical trends and future forecasts.

METHODS: We estimated all-age and age-specific deaths and disability-adjusted life-years (DALYs) attributable to and associated with bacterial AMR for 22 pathogens, 84 pathogen-drug combinations, and 11 infectious syndromes in 204 countries and territories from 1990 to 2021. We collected and used multiple cause of death data, hospital discharge data, microbiology data, literature studies, single drug resistance profiles, pharmaceutical sales, antibiotic use surveys, mortality surveillance, linkage data, outpatient and inpatient insurance claims data, and previously published data, covering 520 million individual records or isolates and 19 513 study-location-years. We used statistical modelling to produce estimates of AMR burden for all locations, including those with no data. Our approach leverages the estimation of five broad component quantities: the number of deaths involving sepsis; the proportion of infectious deaths attributable to a given infectious syndrome; the proportion of infectious syndrome deaths attributable to a given pathogen; the percentage of a given pathogen resistant to an antibiotic of interest; and the excess risk of death or duration of an infection associated with this resistance. Using these components, we estimated disease burden attributable to and associated with AMR, which we define based on two counterfactuals; respectively, an alternative scenario in which all drug-resistant infections are replaced by drug-susceptible infections, and an alternative scenario in which all drug-resistant infections were replaced by no infection. Additionally, we produced global and regional forecasts of AMR burden until 2050 for three scenarios: a reference scenario that is a probabilistic forecast of the most likely future; a Gram-negative drug scenario that assumes future drug development that targets Gram-negative pathogens; and a better care scenario that assumes future improvements in health-care quality and access to appropriate antimicrobials. We present final estimates aggregated to the global, super-regional, and regional level.

FINDINGS: In 2021, we estimated 4·71 million (95% UI 4·23-5·19) deaths were associated with bacterial AMR, including 1·14 million (1·00-1·28) deaths attributable to bacterial AMR. Trends in AMR mortality over the past 31 years varied substantially by age and location. From 1990 to 2021, deaths from AMR decreased by more than 50% among children younger than 5 years yet increased by over 80% for adults 70 years and older. AMR mortality decreased for children younger than 5 years in all super-regions, whereas AMR mortality in people 5 years and older increased in all super-regions. For both deaths associated with and deaths attributable to AMR, meticillin-resistant Staphylococcus aureus increased the most globally (from 261 000 associated deaths [95% UI 150 000-372 000] and 57 200 attributable deaths [34 100-80 300] in 1990, to 550 000 associated deaths [500 000-600 000] and 130 000 attributable deaths [113 000-146 000] in 2021). Among Gram-negative bacteria, resistance to carbapenems increased more than any other antibiotic class, rising from 619 000 associated deaths (405 000-834 000) in 1990, to 1·03 million associated deaths (909 000-1·16 million) in 2021, and from 127 000 attributable deaths (82 100-171 000) in 1990, to 216 000 (168 000-264 000) attributable deaths in 2021. There was a notable decrease in non-COVID-related infectious disease in 2020 and 2021. Our forecasts show that an estimated 1·91 million (1·56-2·26) deaths attributable to AMR and 8·22 million (6·85-9·65) deaths associated with AMR could occur globally in 2050. Super-regions with the highest all-age AMR mortality rate in 2050 are forecasted to be south Asia and Latin America and the Caribbean. Increases in deaths attributable to AMR will be largest among those 70 years and older (65·9% [61·2-69·8] of all-age deaths attributable to AMR in 2050). In stark contrast to the strong increase in number of deaths due to AMR of 69·6% (51·5-89·2) from 2022 to 2050, the number of DALYs showed a much smaller increase of 9·4% (-6·9 to 29·0) to 46·5 million (37·7 to 57·3) in 2050. Under the better care scenario, across all age groups, 92·0 million deaths (82·8-102·0) could be cumulatively averted between 2025 and 2050, through better care of severe infections and improved access to antibiotics, and under the Gram-negative drug scenario, 11·1 million AMR deaths (9·08-13·2) could be averted through the development of a Gram-negative drug pipeline to prevent AMR deaths.

INTERPRETATION: This study presents the first comprehensive assessment of the global burden of AMR from 1990 to 2021, with results forecasted until 2050. Evaluating changing trends in AMR mortality across time and location is necessary to understand how this important global health threat is developing and prepares us to make informed decisions regarding interventions. Our findings show the importance of infection prevention, as shown by the reduction of AMR deaths in those younger than 5 years. Simultaneously, our results underscore the concerning trend of AMR burden among those older than 70 years, alongside a rapidly ageing global community. The opposing trends in the burden of AMR deaths between younger and older individuals explains the moderate future increase in global number of DALYs versus number of deaths. Given the high variability of AMR burden by location and age, it is important that interventions combine infection prevention, vaccination, minimisation of inappropriate antibiotic use in farming and humans, and research into new antibiotics to mitigate the number of AMR deaths that are forecasted for 2050.

FUNDING: UK Department of Health and Social Care's Fleming Fund using UK aid, and the Wellcome Trust.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050. Lancet. 2024. PMID: 39299261. doi:10.1016/S0140-6736(24)01867-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。